Tuomo Tapani Pätsi

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Founded in 2010, Celgene International SARL is a Swiss bio-pharmaceutical company that operates to discover, develop, and commercialize therapies for unmet medical needs in cancer. Part of Bristol Myers Squibb Co., the company is based in Boudry, Switzerland.

Celgene Ltd. engages in the development of human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company was founded on June 2, 2015 and is headquartered in Uxbridge, the United Kingdom.

Part of Bristol Myers Squibb Co., Celgene Europe Ltd. is a British company that engages in research and development in pharmaceutical products. The company is based in Middlesex, UK.

Part of Bristol Myers Squibb Co., Juno Therapeutics GmbH is a German company that researches and develops cellular therapies. The company is based in Munich, Germany. The CEOs of the company are David Walter Pignolet, Lothar Germeroth. Juno Therapeutics was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on May 11, 2015 for $232.80 million.

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Aqsens Health Oy is a Finnish health and biotechnology start-up that specializes in developing non-invasive screening tests for high-impact diseases. The private company is located in Finland. The Finnish company's current research focuses on developing a mobile screening platform for infectious diseases and a reliable prostate cancer screening test using their e-trf technology and novel phage-based biosensors. The company's non-invasive screening and diagnostics technology is based on the e-trf method and bacteriophage biosensors.